Physician profile
Munazza Khan
NPI 1609897479
$2,931.73
in general payments reported to CMS, 2019-2025
27 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $109 · 2021: $433 · 2022: $380 · 2023: $381 · 2024: $796 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $669.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $376.00 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.79 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $181.28 | 2019-2022 | |
| Pfizer INC. | $160.93 | 2019-2025 | |
| Lilly USA, LLC | $129.12 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $124.73 | 2024-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $118.00 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $111.93 | 2019-2021 | |
| Exact Sciences Corporation | $110.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.90 | 2022-2025 | |
| Novo Nordisk INC | $107.08 | 2019-2024 | Rybelsus, Ozempic |
| Eisai INC. | $70.40 | 2021-2022 | |
| Allergan, INC. | $44.89 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $35.08 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $34.95 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cmp Pharma, INC. | $28.38 | 2022 | |
| Sumitomo Pharma America, INC. | $28.13 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $23.76 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $23.71 | 2023 | Gvoke Hypopen |
| Sun Pharmaceutical Industries INC. | $23.44 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.89 | 2022 | |
| Dexcom, INC. | $18.29 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.26 | 2019 | |
| Radius Health, INC. | $15.99 | 2021 | |
| Shield Therapeutics INC | $15.09 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munazza Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.